Our Take
Brinsupri's clinical dominance is real and funded, but pricing policy risk—not efficacy—now controls its market trajectory outside the US.
Why it matters
Non-cystic fibrosis bronchiectasis has no approved anti-inflammatory option until now, meaning real clinical need exists. But regulatory delay signals that pricing pressure, not medical proof, determines when patients actually access approved drugs.
Do this week
Pulmonologists in Europe: document your NCFB patient census and treatment gaps this month so you can credibly advocate for reimbursement once Brinsupri's European launch clears.
Brinsupri posts $208M in first-quarter revenue, pauses Europe entry
Insmed reported $207.9 million in net sales for Brinsupri (brensocatib) in Q1 2026, reaffirming full-year guidance of at least $1 billion (company-reported). The drug, approved by the FDA in August 2025 as the first DPP-1 inhibitor for non-cystic fibrosis bronchiectasis (NCFB), secured UK approval in February 2026 and European approval in November 2025. Despite regulatory clearance, Insmed delayed the European commercial launch, citing uncertainty around the US government's Most Favored Nation (MFN) drug pricing policy and its implications for international pricing strategy.
At the 2026 American Thoracic Society conference in May, Insmed showcased post-hoc analysis of the Phase III ASPEN trial showing that both 10mg and 25mg doses of brensocatib produced numerical improvements in patient-reported respiratory symptoms and quality-of-life scores versus placebo (per trial data presented). In the placebo arm, Quality of Life-Bronchiectasis Respiratory Symptoms scores improved from 60.0 to 66.3 over 52 weeks; the 25mg dose showed improvement from 61.9 to 70.3. Symptom relief was most pronounced in patients with severe exacerbations requiring hospitalization or IV antibiotics.
Clinical evidence is solid; commercial strategy is pricing-driven
Brinsupri addresses a concrete gap. A survey of 1,050 NCFB patients and 88 caregivers revealed that 76.8% experienced health status decline after exacerbation, with residual anxiety about future flare-ups even during stable periods (per Insmed survey data). Prior to Brinsupri, treatment relied on off-label antibiotics and supportive care, with no targeted anti-inflammatory option. The drug's mechanism, DPP-1 inhibition targeting neutrophilic inflammation, offers a non-antibiotic alternative.
However, the European launch delay exposes the limits of clinical approval. Brinsupri has regulatory green lights across major markets, yet pricing policy uncertainty—not efficacy doubt—controls patient access. Insmed's decision signals that US government price negotiations create downstream friction in international strategy, potentially delaying care for European NCFB patients for months or longer pending policy clarity.
Build the case before supply appears
Pulmonologists outside the US should document existing NCFB patient cohorts and current treatment gaps now. Survey current practice: how many patients are on chronic antibiotics for symptom suppression? How many have declined therapy due to side effects or exacerbation frequency? This baseline data will serve two purposes. First, it creates a clinical justification ready when Brinsupri becomes available, accelerating adoption once the commercial launch clears. Second, it provides reimbursement bodies with real evidence of unmet need, strengthening negotiating leverage on pricing and coverage when the therapy finally enters the regional market. Insmed's own ATS initiatives—including a landmark 36-month EHR analysis to improve NCFB diagnosis across seven US academic health systems—underscore that disease awareness and case identification are prerequisite to uptake. European sites can accelerate this legwork independently.